IFI44L

Across TCGA pan-cancer cohorts, IFI44L Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated IFI44L data layer compared with 23 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher IFI44L Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated IFI44L expression acts as an unfavorable survival marker.

LUAD, MESO, and BLCA are the cancer types where IFI44L Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.053	0.835	<.001	36	view →
MESO	OS	Median	II,III,IV	0.071	0.572	<.001	24	view →
BLCA	OS	Median	IV	0.130	0.599	.002	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LIHC	DFS	Median	All	0.020	0.554	<.001	6	view →
HNSC	DFS	Median	II,III,IV	0.169	0.554	.041	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

IFI44L–LUAD (OS)

Open the LUAD breakdown →